{"id":"interleukin-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Capillary leak syndrome"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Oliguria/acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-2 binds to the IL-2 receptor on lymphocytes, triggering T cell activation, expansion, and differentiation into effector and memory cells. It also enhances natural killer cell activity and promotes immune-mediated tumor destruction. This mechanism leverages the body's own immune system to target malignant cells.","oneSentence":"Interleukin-2 (IL-2) is a cytokine that activates and proliferates T cells and natural killer cells to enhance immune response against cancer and infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:24.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT03030378","phase":"PHASE1","title":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-30","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT02557074","phase":"PHASE3","title":"TREg Activation in the Treatment of the PELADE (Alopecia Areata)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-12-15","conditions":"Alopecia Areata","enrollment":44},{"nctId":"NCT06730126","phase":"PHASE2","title":"Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-10","conditions":"Autoimmune Lymphoproliferative Syndrome","enrollment":15},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06991361","phase":"PHASE1","title":"Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD","status":"NOT_YET_RECRUITING","sponsor":"Leslie Kean","startDate":"2026-05-01","conditions":"Graft Versus Host Disease (cGvHD)","enrollment":21},{"nctId":"NCT06910475","phase":"NA","title":"Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study","status":"ENROLLING_BY_INVITATION","sponsor":"Catholic University of Brasília","startDate":"2025-04-01","conditions":"Kidney Disease, Chronic, Kidney Failure Chronic","enrollment":1600},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT04977453","phase":"PHASE1, PHASE2","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2021-08-02","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer","enrollment":317},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT06946680","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-18","conditions":"High-grade Glioma","enrollment":18},{"nctId":"NCT06052618","phase":"PHASE2","title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-17","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease","enrollment":75},{"nctId":"NCT06826547","phase":"EARLY_PHASE1","title":"Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Tunis El Manar","startDate":"2025-02-15","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin, Fasting, Intermittent, Ramadan Fasting","enrollment":100},{"nctId":"NCT05353530","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2023-07-25","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":39},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT06557265","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)","status":"RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2024-06-13","conditions":"Lupus Nephritis, Primary Membranous Nephropathy","enrollment":96},{"nctId":"NCT04332653","phase":"PHASE1, PHASE2","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"NeoImmuneTech","startDate":"2020-06-10","conditions":"Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":215},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT05600920","phase":"PHASE1, PHASE2","title":"A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-11-06","conditions":"Idiopathic CD4 Lymphopenia","enrollment":60},{"nctId":"NCT04695327","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy","status":"COMPLETED","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2021-01-11","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT05877599","phase":"PHASE1","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-12","conditions":"Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma","enrollment":46},{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":"Early Stage Triple Negative ER Low Breast Cancer","enrollment":""},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT04205838","phase":"PHASE2","title":"Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-03-04","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease","enrollment":23},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02340676","phase":"PHASE2","title":"A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-02","conditions":"Chronic Graft-versus-host-disease","enrollment":25},{"nctId":"NCT07423975","phase":"PHASE2","title":"Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-03-01","conditions":"Stroke Acute, Endovascular Treatment","enrollment":159},{"nctId":"NCT04052334","phase":"PHASE1","title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-27","conditions":"Sarcoma","enrollment":9},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT01366092","phase":"PHASE2","title":"Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Chronic Graft-versus-host Disease","enrollment":35},{"nctId":"NCT01659151","phase":"PHASE2","title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-08-03","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":13},{"nctId":"NCT07410494","phase":"PHASE1, PHASE2","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)","enrollment":85},{"nctId":"NCT06713174","phase":"NA","title":"Interleukin 8 and10 Levels Changes in Teeth With Necrotic Pulp and Apical Periodontitis","status":"COMPLETED","sponsor":"Faculty of Dental Medicine for Girls","startDate":"2024-12-15","conditions":"Pulp and Periapical Tissue Disease, Patients With Pulp Necrosis and Apical Periodontitis","enrollment":22},{"nctId":"NCT07410676","phase":"PHASE1, PHASE2","title":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Sarcoma, Leukaemia","enrollment":83},{"nctId":"NCT06237881","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Advanced Solid Tumor, Melanoma, Lung Neoplasms","enrollment":15},{"nctId":"NCT05964465","phase":"PHASE4","title":"Mechanisms of Smell Improvement With Dupilumab.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-08-10","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":60},{"nctId":"NCT06974877","phase":"PHASE1","title":"Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Cryopyrin-Associated Periodic Syndromes, Amyloidosis","enrollment":30},{"nctId":"NCT01875601","phase":"PHASE1","title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-11","conditions":"Solid Tumors, Brain Tumors, Sarcoma","enrollment":16},{"nctId":"NCT07288073","phase":"PHASE2","title":"TIL Therapy in cSCC and MCC","status":"RECRUITING","sponsor":"Karam Khaddour, MD, MS","startDate":"2026-02-10","conditions":"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT07052305","phase":"PHASE1","title":"NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-02-10","conditions":"Large B-cell Lymphoma","enrollment":24},{"nctId":"NCT03761108","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-01-23","conditions":"Multiple Myeloma","enrollment":387},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT06598371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Select Advanced Solid Tumors","enrollment":141},{"nctId":"NCT05544448","phase":"NA","title":"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-02","conditions":"Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia","enrollment":67},{"nctId":"NCT06287528","phase":"PHASE1","title":"A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-23","conditions":"Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult","enrollment":18},{"nctId":"NCT02964078","phase":"PHASE2","title":"Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-04-25","conditions":"Kidney Cancer","enrollment":27},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT07394322","phase":"NA","title":"Interleukin-6 in the Development of Meconium Aspiration Syndrome in Newborn","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-01-01","conditions":"Meconium Aspiration Syndrome","enrollment":120},{"nctId":"NCT01937468","phase":"PHASE1","title":"Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-11","conditions":"Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells","enrollment":25},{"nctId":"NCT04263831","phase":"PHASE1, PHASE2","title":"Low Dose IL-2 for the Treatment of Crohn's Disease","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-03-11","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT05676827","phase":"","title":"Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2023-09-01","conditions":"TMD, Masticatory Muscle Pain","enrollment":102},{"nctId":"NCT03666000","phase":"PHASE1","title":"Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"Imugene Limited","startDate":"2019-03-11","conditions":"Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT07060638","phase":"PHASE2","title":"Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial","status":"RECRUITING","sponsor":"Samer Gawrieh","startDate":"2026-01-27","conditions":"Alcohol-associated Hepatitis","enrollment":216},{"nctId":"NCT04562129","phase":"PHASE2","title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-09-24","conditions":"Melanoma Stage III, Melanoma Stage IV, Inoperable Disease","enrollment":29},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT03474497","phase":"PHASE1, PHASE2","title":"UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Megan Daly, MD","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT05309616","phase":"PHASE2","title":"Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2025-02-20","conditions":"Idiopathic Subglottic Stenosis","enrollment":10},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03968913","phase":"EARLY_PHASE1","title":"Biologic Therapy to Prevent Osteoarthritis After ACL Injury","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2021-09-15","conditions":"Anterior Cruciate Ligament Injuries","enrollment":32},{"nctId":"NCT05357027","phase":"PHASE1, PHASE2","title":"HPV16 E6 TCR T Cells for Cervical Carcinoma","status":"TERMINATED","sponsor":"TCRCure Biopharma Ltd.","startDate":"2022-08-10","conditions":"Cervical Carcinoma","enrollment":5},{"nctId":"NCT06736379","phase":"PHASE1","title":"Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer","status":"RECRUITING","sponsor":"VLP Therapeutics","startDate":"2025-05-13","conditions":"Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors","enrollment":41},{"nctId":"NCT07192900","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","status":"RECRUITING","sponsor":"David Bartlett, MD","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT07343934","phase":"PHASE1","title":"huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-02","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":6},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05989828","phase":"PHASE1","title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"University of Southern California","startDate":"2024-12-17","conditions":"Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT07333105","phase":"NA","title":"Whole Body Vibration Versus Aerobic Training on Interleukin 6 and Endurance After Renal Transplantation","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-09-01","conditions":"Whole Body Vibration, Aerobic Training, Interleukin 6","enrollment":60},{"nctId":"NCT02739412","phase":"PHASE2","title":"Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":6},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT06255028","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Century Therapeutics, Inc.","startDate":"2025-02-06","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies","enrollment":6},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05628883","phase":"PHASE1","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-11-22","conditions":"Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma","enrollment":17},{"nctId":"NCT05611710","phase":"PHASE2","title":"Anakinra in Dengue With Hyperinflammation ( AnaDen )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2023-01-02","conditions":"Dengue, Dengue With Warning Signs, Severe Dengue","enrollment":160},{"nctId":"NCT06138587","phase":"PHASE1","title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-24","conditions":"Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid","enrollment":15},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT05307874","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImCheck Therapeutics","startDate":"2022-05-04","conditions":"Solid Tumor, Adult","enrollment":56},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT04155710","phase":"PHASE1","title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2020-02-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":7},{"nctId":"NCT06125197","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2024-07-23","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT01319565","phase":"PHASE2","title":"Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-24","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":102}],"_emaApprovals":[],"_faersSignals":[{"count":70,"reaction":"OFF LABEL USE"},{"count":65,"reaction":"PYREXIA"},{"count":44,"reaction":"HYPOTENSION"},{"count":40,"reaction":"PAIN"},{"count":37,"reaction":"DISEASE PROGRESSION"},{"count":36,"reaction":"NAUSEA"},{"count":33,"reaction":"FATIGUE"},{"count":30,"reaction":"DIARRHOEA"},{"count":27,"reaction":"CARDIOTOXICITY"},{"count":26,"reaction":"CHILLS"}],"_approvalHistory":[],"publicationCount":36220,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IL-2","Aldesleukin; IL-2 or Proleukin®","IL2","Proleukin","Interleukin-2"],"phase":"marketed","status":"active","brandName":"Interleukin 2","genericName":"Interleukin 2","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interleukin-2 (IL-2) is a cytokine that activates and proliferates T cells and natural killer cells to enhance immune response against cancer and infections. Used for Metastatic renal cell carcinoma, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}